secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004045
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport reports positive Phase 1 RAP-219 data; CMO steps down
-------------------------------------------------------------

- PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.
- MAD-2 trial: no sedation or motoric impairment observed; all adverse events Grade 1 or 2.
- Phase 2a focal epilepsy trial on track; topline data expected mid-2025.
- Bradley Galer, M.D., stepped down as Chief Medical Officer; search for successor underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525004045/0001193125-25-004045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525004045/d925938d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer